PSNL
Personalis, Inc.
+0.09 (+0.56%)16.20USD2.3M成交股數1.7B市值–本益比(近四季)24.8股價營收比+30.0%營收年增(近四季)2026-11-03下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 22.4M+30% | 15.5M-25% | 17.3M-33% | 14.5M-36% | 17.2M-12% | 20.6M+5% | 25.7M+41% | 22.6M+35% | 19.5M | 19.7M | 18.2M | 16.7M |
| 營業成本 | 17.6M | 15.2M | 15.4M | 12.6M | 12.4M | 13.4M | 17.0M | 14.5M | 14.0M | 14.5M | 14.8M | 11.9M |
| 毛利 | 4.7M-0% | 281K-96% | 1.9M-78% | 1.9M-76% | 4.8M-13% | 7.2M+38% | 8.7M+151% | 8.0M+68% | 5.5M | 5.2M | 3.5M | 4.8M |
| 毛利率 | 21.2% | 1.8% | 11.0% | 13.2% | 27.6% | 35.0% | 34.0% | 35.6% | 28.1% | 26.5% | 19.1% | 28.7% |
| 研發費用 | 16.3M | 14.5M | 13.1M | 12.2M | 12.4M | 12.6M | 11.7M | 13.0M | 12.8M | 13.6M | 16.7M | 17.9M |
| 銷售管理費用 | 22.0M | 17.9M | 14.1M | 13.0M | 14.2M | 12.3M | 11.4M | 12.0M | 11.6M | 11.5M | 12.0M | 12.1M |
| 營業利益 | −33.6M+54% | −32.2M+82% | −25.3M+76% | −23.3M+38% | −21.8M+15% | −17.7M-26% | −14.4M-53% | −16.9M-33% | −18.9M | −24.0M | −30.8M | −25.3M |
| 營業利益率 | -150.2% | -207.9% | -145.7% | -160.7% | -126.7% | -85.9% | -55.9% | -74.8% | -96.7% | -121.8% | -168.8% | -151.8% |
| 稅後淨利 | −31.7M+58% | −30.0M+91% | −23.8M-39% | −21.7M+69% | −20.1M+55% | −15.8M-41% | −39.1M+34% | −12.8M-47% | −13.0M | −26.6M | −29.1M | −24.0M |
| 淨利率 | -141.7% | -194.1% | -137.3% | -149.4% | -116.6% | -76.4% | -152.0% | -56.7% | -66.4% | -135.1% | -159.5% | -143.5% |
| 稀釋 EPS | -0.30+30% | -0.29+61% | -0.26-59% | -0.240% | -0.23-12% | -0.18-67% | -0.64+7% | -0.24-52% | -0.26 | -0.54 | -0.60 | -0.50 |
| 稀釋股數 | 105M | 104M | 89.2M | 88.7M | 88.5M | 87.5M | 61.1M | 52.4M | 50.7M | 48.2M | 48.7M | 47.7M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 94.0M | 73.6M | 124M | 50.0M | 53.4M | 71.0M | 75.8M | 47.7M | 44.0M | 57.0M | 72.2M | 97.2M |
| 應收帳款 | 15.1M | 13.0M | 16.2M | 14.4M | 10.0M | 11.0M | 13.5M | 12.9M | 11.3M | 17.7M | 13.7M | 10.1M |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 312M | 325M | 334M | 243M | 259M | 273M | 240M | 186M | 195M | 225M | 227M | 249M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 77.0M | 70.6M | 73.0M | 71.4M | 67.9M | 66.0M | 73.1M | 73.2M | 74.6M | 95.7M | 75.4M | 73.0M |
| 股東權益 | 235M | 255M | 261M | 171M | 191M | 207M | 167M | 112M | 121M | 129M | 151M | 176M |
| 負債比 | 24.7% | 21.7% | 21.8% | 29.4% | 26.2% | 24.1% | 30.5% | 39.5% | 38.2% | 42.5% | 33.3% | 29.3% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −22.5M+25% | – | – | – | −18.0M | – | – | −20.4M | – | – | – |
| 資本支出 | – | 3.2M | – | – | – | 2.5M | – | – | 104K | – | – | – |
| 自由現金流 | – | −25.7M+25% | – | – | – | −20.5M | – | – | −20.5M | – | – | – |
| 折舊攤銷 | 2.4M | 2.4M | 2.6M | 2.4M | 2.5M | 2.6M | 2.8M | 2.8M | 2.8M | 2.9M | 2.8M | 2.8M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -165.9% | – | – | – | -99.4% | – | – | -105.1% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
主要客戶2025 年度 · 69.6M
| Pharma Testing Services | 48.7M | 69.9% | -4.5% |
|---|---|---|---|
| Population Sequencing | 11.8M | 16.9% | +58.4% |
| Enterprise Sales | 5.9M | 8.4% | -76.8% |
| Clinical Diagnostic | 2.0M | 2.9% | +165.9% |
| 其他 | 1.3M | 1.9% | +980.3% |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 69.6M | -17.7% | −81.3M | -116.7% | -0.91 | −79.5M |
| FY2024 | 84.6M | +15.2% | −81.3M | -96.1% | -1.37 | −46.8M |
| FY2023 | 73.5M | +13.0% | −108M | -147.4% | -2.25 | −67.2M |
| FY2022 | 65.0M | -23.9% | −113M | -174.2% | -2.48 | −120M |
| FY2021 | 85.5M | +8.7% | −65.2M | -76.3% | -1.49 | −81.9M |
| FY2020 | 78.6M | +20.6% | −41.3M | -52.5% | -1.20 | −45.9M |
| FY2019 | 65.2M | +72.6% | −25.1M | -38.5% | -1.39 | −26.5M |
| FY2018 | 37.8M | – | −19.9M | -52.6% | -6.49 | −2.3M |